BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,354,694 | -31.8% | 49,283 | -18.2% | 0.16% | -27.3% |
| Q2 2023 | $4,918,371 | +10.0% | 60,252 | -0.0% | 0.23% | +4.6% |
| Q1 2023 | $4,471,951 | -14.1% | 60,277 | -4.0% | 0.22% | -18.4% |
| Q4 2022 | $5,204,367 | -1.3% | 62,794 | +238.3% | 0.27% | -8.3% |
| Q3 2022 | $5,271,000 | -6.4% | 18,560 | +14.2% | 0.29% | -1.0% |
| Q2 2022 | $5,632,000 | -10.4% | 16,246 | +11.9% | 0.29% | +9.3% |
| Q1 2022 | $6,284,000 | +11.0% | 14,512 | +32.7% | 0.27% | +21.8% |
| Q4 2021 | $5,659,000 | +121.1% | 10,939 | +107.1% | 0.22% | +107.5% |
| Q3 2021 | $2,559,000 | +107.4% | 5,282 | +92.8% | 0.11% | +112.0% |
| Q2 2021 | $1,234,000 | +22.5% | 2,740 | +3.9% | 0.05% | +13.6% |
| Q1 2021 | $1,007,000 | +34.8% | 2,636 | +12.0% | 0.04% | +25.7% |
| Q4 2020 | $747,000 | +31.3% | 2,353 | +2.5% | 0.04% | +16.7% |
| Q3 2020 | $569,000 | +6.0% | 2,295 | +12.8% | 0.03% | -3.2% |
| Q2 2020 | $537,000 | +103.4% | 2,035 | +46.2% | 0.03% | +63.2% |
| Q1 2020 | $264,000 | – | 1,392 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |